Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP837492.RA1XyhoBhGp4v2SopAQeJK59_9QKtu07WwN2ztOYRg-cQ130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP837492.RA1XyhoBhGp4v2SopAQeJK59_9QKtu07WwN2ztOYRg-cQ130_assertion type Assertion NP837492.RA1XyhoBhGp4v2SopAQeJK59_9QKtu07WwN2ztOYRg-cQ130_head.
- NP837492.RA1XyhoBhGp4v2SopAQeJK59_9QKtu07WwN2ztOYRg-cQ130_assertion wasGeneratedBy ECO_0000203 NP837492.RA1XyhoBhGp4v2SopAQeJK59_9QKtu07WwN2ztOYRg-cQ130_provenance.
- NP837492.RA1XyhoBhGp4v2SopAQeJK59_9QKtu07WwN2ztOYRg-cQ130_assertion wasDerivedFrom befree-20150227 NP837492.RA1XyhoBhGp4v2SopAQeJK59_9QKtu07WwN2ztOYRg-cQ130_provenance.
- NP837492.RA1XyhoBhGp4v2SopAQeJK59_9QKtu07WwN2ztOYRg-cQ130_assertion SIO_000772 22271575 NP837492.RA1XyhoBhGp4v2SopAQeJK59_9QKtu07WwN2ztOYRg-cQ130_provenance.
- NP837492.RA1XyhoBhGp4v2SopAQeJK59_9QKtu07WwN2ztOYRg-cQ130_assertion evidence source_evidence_literature NP837492.RA1XyhoBhGp4v2SopAQeJK59_9QKtu07WwN2ztOYRg-cQ130_provenance.
- NP837492.RA1XyhoBhGp4v2SopAQeJK59_9QKtu07WwN2ztOYRg-cQ130_assertion description "[Enzymatic inhibitors of Janus kinase 2 (JAK2) are in clinical development for the treatment of myeloproliferative neoplasms (MPNs), B cell acute lymphoblastic leukemia (B-ALL) with rearrangements of the cytokine receptor subunit cytokine receptor-like factor 2 (CRLF2), and other tumors with constitutive JAK2 signaling.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP837492.RA1XyhoBhGp4v2SopAQeJK59_9QKtu07WwN2ztOYRg-cQ130_provenance.